Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Clasificación en acciones #40889
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Precio por acción
$0.0127
Última sincronización: 2026-08-12
Capitalización bursátil
$66.48K
Cambio (1 día)
-2.31%
Cambio (1 año)
-67.44%
País
US
Comercio Vincerx Pharma, Inc. (VINC)

Categoría

Historial de rendimiento por dividendo de Vincerx Pharma, Inc. (VINC)
Rendimiento por dividendo (TTM) de Vincerx Pharma, Inc. (símbolo bursátil: VINC) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Vincerx Pharma, Inc. (VINC) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE